Search Within

CTCR Scholars

Formats
  1. Meeting Abstract (873)
  2. Journal Article (564)
  3. Review (72)
  4. Research Letter (38)
  5. Editorial (29)
  6. Correspondence (24)
  7. Miscellaneous (17)
  8. Book Section (11)
  9. Guidelines (7)
  10. Conference Paper (4)
Groups
  1. Department of Medicine (1415)
  2. Hematologic Malignancies, Division of (1082)
  3. MSK Grad Students (1018)
  4. Center for Hematologic Malignancies (985)
  5. Master of Science in Clinical and Translational Cancer Research (983)
  6. Survivorship Research (917)

More Groups

People
  1. Sergio Giralt (553)
  2. Miguel-Angel Perales (411)
  3. Michael Scordo (385)
  4. Gunjan Shah (341)
  5. Sean Devlin (333)
  6. Parastoo Dahi (305)

More People

Years
  1. 2025 (98)
  2. 2024 (251)
  3. 2023 (261)
  4. 2022 (230)
  5. 2021 (166)
  6. 2020 (211)

More Years

Publications
  1. Blood (318)
  2. Biology of Blood and Marrow Transplantation (187)
  3. Journal of Clinical Oncology (144)
  4. Annals of Surgical Oncology (83)
  5. Bone Marrow Transplantation (65)
  6. Transplantation and Cellular Therapy (56)

More Publications

Publishers
  1. Elsevier Inc. (390)
  2. American Society of Hematology (372)
  3. American Society of Clinical Oncology (158)
  4. Nature Publishing Group (134)
  5. Springer (102)
  6. American Association for Cancer Research (65)

More Publishers

Results (1639)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • VRd versus KRd safety profiles in newly diagnosed multiple myeloma patients using real-world evidence data from a single institution: VRd has high rates of chronic neuropathy, and KRd has low rates of cardiopulmonary or renal toxicities when using optimized IV fluid management coupled with baseline cardiac workup
    Meeting Abstract

    Tan, C.; Diamond, B.; Hultcrantz, M.; Korde, N.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; Lu, S. X.; Patel, D.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Clinical outcomes of acute myeloid leukemia patients bridged to allogeneic stem cell transplant by venetoclax combination therapy
    Meeting Abstract

    Stahl, M.; Menghrajani, K.; Derkach, A.; DeWolf, S.; Ruiz, J. D.; Ponce, D. M.; Shaffer, B. C.; Tamari, R.; Young, J. W.; Barker, J.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Results of a phase 1 open label dose escalation trial of AB-205 (allogeneic engineered endothelial cell therapy) in adults with lymphoma undergoing high-dose therapy and autologous hematopoietic cell transplantation (HDT-AHCT)
    Meeting Abstract

    Scordo, M.; Budde, L. E.; Abedi, M.; Mulroney, C.; Fakhri, B.; Pawarode, A.; Dholaria, B.; Kavalerchik, E.; Aggarwal, S. K.; Qazilbash, M. H.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders: A population based study including 94,579 cases and 368,348 matched controls
    Meeting Abstract

    Shah, U. A.; Rögnvaldsson, S.; Derkach, A.; Björkholm, M.; Turesson, I.; David, Y.; Hultcrantz, M.; Tan, C.; Hassoun, H.; Korde, N.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A pilot study evaluating lenalidomide and CC-486 in combination with radiotherapy for patients with plasmacytoma (LENAZART study)
    Meeting Abstract

    Shah, U. A.; Werner, K.; Tavitian, E.; Devlin, S.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Tan, C.; Lu, S. X.; Smith, E. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Favorable outcomes among patients with T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era
    Meeting Abstract

    Robin, E. T.; Drill, E.; Batlevi, C. L.; Caron, P.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; Joffe, E.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Secondary graft-versus-host disease (GVHD) prophylaxis with oral proteasome inhibitor ixazomib is associated with low incidence of recurrent, late acute and chronic GVHD and facilitated calcineurin inhibitor taper within the first year post allogeneic stem cell transplantation
    Meeting Abstract

    Rodriguez, N.; Lee, J.; Flynn, L.; Murray, F.; Devlin, S.; Izquierdo, C. S.; Cho, C.; Dahi, P. B.; Giralt, S. A.; Sauter, C. S.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Prognostic factors for North American adult T cell leukemia lymphoma: Defining risk groups using a four-point score prognostic system
    Meeting Abstract

    Rahman, S.; Soto, A. A.; Qunaj, L.; Ye, K.; Pradhan, K.; Thakkar, A.; Cui, Z.; Meron, M. K.; D'Aiello, A.; Lombardo, A.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Investigational CD47-blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: Update from the ongoing first-in-human dose escalation study
    Meeting Abstract

    Patel, K.; Ramchandren, R.; Maris, M.; Lesokhin, A. M.; von Keudell, G. R.; Cheson, B. D.; Zonder, J.; Seymour, E. K.; Catalano, T.; Lin, G. H. Y.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A multi-center biologic assignment trial comparing reduced intensity allogeneic hematopoietic cell transplantation to hypomethylating therapy or best supportive care in patients aged 50-75 with advanced myelodysplastic syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102
    Meeting Abstract

    Nakamura, R.; Saber, W.; Martens, M. J.; Ramirez, A.; Scott, B. L.; Oran, B.; Leifer, E.; Tamari, R.; Mishra, A.; Maziarz, R. T.; more...
    Blood (2020)

    Fulltext@MSK | Save